Melanoma is the deadliest form of skin cancer, and it is one of the cancers whose incidence is increasing fastest in this country. In 2007, melanoma touched the lives of Debra and Leon Black when Debra was diagnosed with the disease. With melanoma incidence rising dramatically and survival for those with advanced disease remaining static at less than 15 percent, the Blacks formed the Melanoma Research Alliance (MRA) under the auspices of the Milken Institute. Thanks to their generous ongoing support of all administrative and fundraising costs, 100% of every donation to MRA goes directly to melanoma research. Our ultimate goal is to find a cure by funding the most promising melanoma research worldwide that will accelerate progress and improve outcomes for patients and all who are at risk.
MRA is the largest private funder of melanoma research. To date, MRA has awarded $48 million to 116 research programs to make transforming advances in the prevention, diagnosis and staging, and treatment of melanoma, including research in biological causes of carcinogenesis, skin screening, biomarkers, imaging, immunotherapy, molecularly targeted therapy, and combination therapy.
Collaboration is at MRA's core—from the team approaches to research that we fund, to the way we find partners who can help us realize our vision. Our allies are also focused on increasing public knowledge about the seriousness of melanoma and ways to reduce risk and improve early detection. MRA is pleased to have the generous support of a growing list of corporate allies in the fight against melanoma to amplify our message and garner the resources necessary to advance our mission. Through a unique partnership with Bruce Springsteen and the Danny Fund, MRA has been engaged in a series of public awareness initiatives urging people to protect themselves from the sun's damaging rays, avoid indoor tanning, and be aware of changes in their skin. Together with our allies and your support, we are working toward the day when no one will suffer or die from melanoma.